Common Supplement May Help Clear ‘Chemo Brain,’ UCLA Study Finds

For decades, chemo brain has been the symptom doctors could name but not fix. Breast cancer survivors finish treatment, their scans come back clean, and then the fog rolls in: forgotten errands, lost words, the same paragraph read three times over. A new UCLA trial may have found a crack in that wall. Every woman who finished the eight-week study reported sharper thinking, and on average the group’s scores moved from clearly impaired to within the normal range.

Oxaloacetate, the supplement at the center of the study, is a substance the body already produces during normal energy metabolism. Researchers tested it in breast cancer survivors with serious thinking and memory problems, reporting their results in the journal JCO Oncology Advances. Participants took the supplement by mouth twice a day for eight weeks, then researchers measured their cognition against their baseline.

More notable than the improvement itself was how large it was. Results came in so strongly early on that researchers changed the trial design while it was still running, a step research teams rarely take unless a treatment is doing far more than expected.

How the Chemo Brain Study Worked

Scientists at UCLA recruited 18 women who had survived early-stage breast cancer and were at least a year past their main treatment and within five years of their original diagnosis, though some were still receiving other cancer therapy. All of them had reported serious cognitive complaints on a standard screening questionnaire, placing them among the lowest 16 percent of women tested for mental sharpness. Most had gone through chemotherapy, and nearly 9 in 10 were currently on hormone-blocking therapy, a common long-term treatment after breast cancer.

Participants took 500 milligrams of the oxaloacetate supplement by mouth, twice daily, for eight weeks. They completed questionnaires about their thinking, memory, fatigue, sleep, mood, and physical health at baseline, at four weeks, and again at eight weeks. Participants also took standardized tests, the same kinds psychologists use to measure focus, memory, and information processing speed.

Sixteen of the 18 women completed the full eight weeks. Two dropped out early because of stomach-related side effects, including one woman whose existing digestive issues from another medication got worse.

From Brain Fog to Clear Thinking: The Results

On the study’s main measure of perceived cognitive impairment, the average participant’s score improved by more than 26 points, a change the researchers said was large enough to matter both statistically and in patients’ daily lives. The group’s average score climbed from well below the impairment cutoff at the start of the study to above the normal cutoff by the end.

Fatigue scores also improved a lot, both the general exhaustion survivors often describe and the specific kind of mental tiredness that makes focusing difficult. Physical functioning, measured through a standard health survey, also jumped noticeably, an unexpected finding the researchers called. Sleep problems showed a trend toward improvement, though it didn’t reach the threshold scientists use to call a result solid. Mood measures for anxiety and depression didn’t change much, but participants hadn’t reported high levels of those symptoms to begin with.

On performance-based tests, which measure how well someone actually does rather than how they feel, researchers saw improvements in skills like planning, organizing, and switching between tasks, as well as in how quickly people could process information. Memory test scores also improved, though the changes weren’t large enough to be considered certain given how few people were tested.

Side effects were mostly limited to the digestive system. Indigestion was the most common complaint, followed by constipation and bloating. None of the recorded side effects were classified as serious, and symptoms resolved within a few weeks after participants stopped taking the supplement.

Why Researchers Cut the Chemo Brain Trial Short

Clinical trials usually follow a strict plan set before they begin to reduce bias, and this one started the same way. Researchers built in checkpoints that let them decide early whether to continue, expand, or stop the study if the treatment wasn’t working. After the first nine participants finished treatment, their cognitive scores improved so much, and so consistently across everyone, that the research team redesigned the study, adding new checkpoints that would let them stop early if the strong results held up. That’s exactly what happened: the trial wrapped up with 18 participants instead of the larger number originally planned.

A hallmark of chemo brain is that scores usually don’t improve when patients retake these standardized tests, so the research team noted real gains on repeat testing.

What This Means for Chemo Brain Treatment

Doctors have tried to solve the chemo brain problem for decades with limited success. Stimulant medications and drugs originally developed for Alzheimer’s disease have been tested before, generally with disappointing results. One large, carefully controlled trial of an Alzheimer’s drug called donepezil in breast cancer patients came back negative entirely. Against that backdrop, a naturally occurring compound showing this level of improvement, with mostly mild and manageable side effects, counts as real news, even coming from a small study.

Researchers quickly point out the obvious limitation: the trial had no placebo group, so no similar patients took a fake pill for comparison. Without that comparison, it’s impossible to rule out that some of the improvement came from expectation rather than the supplement itself. The research team has already received FDA approval to run a follow-up study that includes a placebo comparison, and they expect the trial to begin later this year.

Chemo brain has been dismissed for too long as something survivors simply have to live with. This study won’t settle whether oxaloacetate truly works, but it gives real reason to take the idea seriously and puts pressure on the medical field to finally test it the right way.

Disclaimer: This article describes a small, early-stage (phase II) clinical trial with 18 participants and no placebo group, so its results cannot confirm that the supplement caused the improvements. It is not medical advice. Anyone considering a supplement, especially during or after cancer treatment, should talk with their own doctor first.